Mylan Stock Buy Or Sell May 2026

The company is focusing on higher-margin generic launches and its innovative portfolio, including late-stage assets expected to complete enrollment in 2026. Market Cap: ~$17.25 billion as of April 2026.

Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion . mylan stock buy or sell

Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ). The company is focusing on higher-margin generic launches

Viatris is currently viewed as a value play or income stock rather than a high-growth candidate. Its low valuation and steady dividends may make it a "buy" for long-term holders, while short-term traders might "hold" or "sell" due to flat price targets and operational headwinds. Mylan (formerly NASDAQ: MYL) no longer exists as

Technical analysis indicates a recent "sell signal" from a pivot top point reached in late April 2026. Financial Health & Outlook